Medigen Biotechnology Corp. (TPEX: 3176)

Medigen Biotechnology Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	1,253	2,223	2,041	2,145	2,207	813.69
Short-Term Investments	1,217	2,364	3,040	800	-	25.21
Trading Asset Securities	0.3	0.49	54.23	53.6	54.2	77.22
Cash & Short-Term Investments	2,470	4,588	5,135	2,998	2,261	916.11
Cash Growth	-44.60%	-10.67%	71.28%	32.62%	146.78%	-20.02%
Accounts Receivable	417.83	328.89	398.31	800.22	151.21	151.25
Other Receivables	30.89	124.72	66.37	35.46	130.51	3.35
Receivables	448.72	453.61	464.69	835.68	281.72	154.6
Inventory	619.18	546.91	692.62	752.87	323.29	135.27
Prepaid Expenses	-	33.61	382.35	99.59	-	-
Other Current Assets	130.91	86.4	57.93	231.96	155.9	106.15
Total Current Assets	3,669	5,708	6,733	4,918	3,022	1,312
Property, Plant & Equipment	1,964	2,043	2,198	2,189	2,166	2,540
Long-Term Investments	610.42	292.87	307.33	363.71	156.49	222.47
Goodwill	-	76.18	76.18	76.18	76.18	76.18
Other Intangible Assets	101.73	30.36	36.9	48.08	79.34	105.3
Long-Term Deferred Tax Assets	326.07	327.5	480.94	522.18	555.68	519.2
Other Long-Term Assets	74.77	49.1	150.42	81.75	97.02	53.26
Total Assets	6,745	8,527	9,982	8,199	6,152	4,829
Accounts Payable	352.04	122.57	185.01	163.94	110	107.72
Short-Term Debt	235	402.6	328	300	475	375
Current Portion of Long-Term Debt	40.65	1,728	28.86	21.34	21.39	110.89
Current Portion of Leases	17.41	17.32	13.13	3.32	3.02	11.46
Current Income Taxes Payable	4.27	24.63	22.99	-	-	-
Current Unearned Revenue	229.7	135	130.4	244.42	113.92	101.89
Other Current Liabilities	21.94	349.37	343.94	331.89	210.47	223.5
Total Current Liabilities	901	2,780	1,052	1,065	933.8	930.46
Long-Term Debt	420.61	449.1	2,129	470.77	486.37	846.01
Long-Term Leases	266.77	267.53	275.32	196.64	195.67	333.46
Long-Term Unearned Revenue	-	-	-	-	-	0.26
Long-Term Deferred Tax Liabilities	14.31	14.15	14.24	14.35	18.15	21.99
Other Long-Term Liabilities	10.28	10.28	29.53	15.89	7.62	2.13
Total Liabilities	1,620	3,530	3,511	1,773	1,653	2,144
Common Stock	1,393	1,393	1,394	1,394	1,390	1,390
Additional Paid-In Capital	518.3	968.14	1,562	1,109	1,101	298.22
Retained Earnings	-240.23	-747.51	-727.98	-52.82	-631.38	-300.99
Comprehensive Income & Other	8.8	-22.45	-34.12	-54.96	-44.37	-25.97
Total Common Equity	1,680	1,592	2,194	2,394	1,815	1,361
Minority Interest	3,446	3,405	4,277	4,032	2,684	1,324
Shareholders' Equity	5,125	4,997	6,471	6,426	4,499	2,685
Total Liabilities & Equity	6,745	8,527	9,982	8,199	6,152	4,829
Total Debt	980.44	2,865	2,774	992.07	1,181	1,677
Net Cash (Debt)	1,489	1,723	2,361	2,006	1,079	-760.71
Net Cash Growth	-10.50%	-27.03%	17.68%	85.87%	-	-
Net Cash Per Share	10.66	12.36	16.97	14.44	7.77	-5.49
Filing Date Shares Outstanding	141.72	139.35	139.45	139.36	138.99	138.99
Total Common Shares Outstanding	141.72	139.35	139.45	139.36	138.99	138.99
Working Capital	2,768	2,928	5,681	3,853	2,088	381.67
Book Value Per Share	11.85	11.42	15.73	17.18	13.06	9.79
Tangible Book Value	1,578	1,485	2,081	2,270	1,660	1,180
Tangible Book Value Per Share	11.14	10.66	14.92	16.29	11.94	8.49
Land	-	330.29	354.04	354.04	354.04	354.04
Buildings	-	1,465	1,506	1,500	1,495	1,494
Machinery	-	1,266	1,240	1,178	1,002	970.83
Construction In Progress	-	21.37	14.54	4.7	17.9	119.35
Leasehold Improvements	-	3.34	3.03	2.55	1.89	1.89

Source: S&P Capital IQ. Standard template. Financial Sources.